Cutaneous T-cell lymphoma (CTCL) is a clonally-derived, skin-invasive malignancy of CD4+ T-lymphocytes with the phenotype of mature helper T-cells. Patients with advanced forms of CTCL characterized by multiple tumors or peripheral blood involvement typically have a poor prognosis. Our previous work has demonstrated that advanced CTCL is characterized by prominent immunologic defects including depressed cell-mediated immunity. A marked defect in IL-12 production in CTCL has also been noted, which may play a role in depressed cell-mediated immunity. Because evidence exists for an antitumor T-cell response and since IL-12 is pivotal in stimulating cytotoxic T-cells, our IL- 12 multicenter trial group has completed a small phase I dose escalation trial of IL-12 with 5 of 9 evaluable patients responding and a phase II single dose trial with 10 of 23 evaluable patients responding. Key observations in these small studies were 1)responses were rapid but were often eventually associated with an IL-12 refractory state 2) the latter may be associated with down modulation of IL-12 receptors on lymphocytes 3) regressing lesions were intensely infiltrated with cytotoxic T-cells and 4) more robust responses occurred at the lower dose of 100 ng/kg used in the phase I trial. This proposal plans another multicenter phase II IL-12 trial using 100 ng/kg sub Q twice weekly for 24 weeks and, because of in vitro synergism with IL-12, adds IL-2 in differing doses at week 13 for all but those with progressive disease. We also propose to investigate the in vivo mechanisms of action of IL-12 by studying 1) skin infiltrating immune cells, 2) cytokine production in situ in skin lesions, and 3) extent of apoptosis within active skin lesions prior to and during IL-12 therapy and correlate this with lesion regression. We will also examine IL-12 responsive NK cell activity and interferon gamma production in concert with IL-12 receptor expression and IL-12 signal transduction prior to and prospectively during therapy to determine if downmodulation of receptors or alteration of Jak-Stat pathways accounts for tolerance to the clinical effects of IL-12. The results of these studies will further improve our understanding of the mechanisms of action of IL-12 and will assist in targeting a more effective dose of IL-12 for CTCL. Moreover, the addition of low-dose IL-2 may yield a more efficacious combination of agents which may synergistically enhance anti-tumor immunity and clinical responses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA089442-02S1
Application #
6791023
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wu, Roy S
Project Start
2001-08-10
Project End
2006-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
2
Fiscal Year
2003
Total Cost
$137,781
Indirect Cost
Name
University of Pennsylvania
Department
Dermatology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hoeller, Christoph; Richardson, Stephen K; Ng, Lai Guan et al. (2009) In vivo imaging of cutaneous T-cell lymphoma migration to the skin. Cancer Res 69:2704-8
Marzec, Michal; Liu, Xiaobin; Kasprzycka, Monika et al. (2008) IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 111:2181-9
Yoon, Jessica S; Newton, Sarah M; Wysocka, Maria et al. (2008) IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sezary syndrome. J Invest Dermatol 128:473-80
Marzec, Michal; Halasa, Krzysztof; Kasprzycka, Monika et al. (2008) Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 68:1083-91
Newton, Sarah B; Yoon, Jessica S; Benoit, Bernice M et al. (2007) Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sezary syndrome. Arch Dermatol 143:661-2
Wysocka, Maria; Newton, Sarah; Benoit, Bernice M et al. (2007) Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 7:524-34
Walsh, Patrick T; Benoit, Bernice M; Wysocka, Maria et al. (2006) A role for regulatory T cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection. J Invest Dermatol 126:690-2
Budgin, Jeanne B; Richardson, Stephen K; Newton, Sarah B et al. (2005) Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 141:315-21
French, Lars E; Huard, Bertrand; Wysocka, Maria et al. (2005) Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L. Blood 105:219-25
Wysocka, Maria; Benoit, Bernice M; Newton, Sarah et al. (2004) Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104:4142-9

Showing the most recent 10 out of 11 publications